LY 345899
Based on 8 publication(s) in Google Scholar
LY 345899 is a Folate analog and is a methylene tetrahydrofolate dehydrogenase (MTHFD1; DC301) and MTHFD2 inbhibitor with IC50 values of 96 nM and 663 nM, respectively and a Ki of 18 nM for MTHFD1.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 10538-99-5
- Formula: C20H21N7O7
- Molecular Weight:471.42
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Covalent Screening Library
HY-L036
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
Amino Acid Metabolism Compound Library
HY-L189
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) LY 345899
More- Cancer Res. 2025 Mar 14;85(6):1113-1129. [Abstract]
- Nat Commun. 2025 Oct 8;16(1):8932. [Abstract]
- Biomed Pharmacother. 2023 May:161:114412. [Abstract]
- Cancers (Basel). 2021 Jan 23;13(3):425. [Abstract]
- J Biol Chem. 2023 Jul;299(7):104909. [Abstract]
- bioRxiv. 2025 Aug 1:2025.07.29.667470. [Abstract]
- Res Sq. 2025 Jul 18.
- bioRxiv. 2021 Feb 3.
Biological Activity
Ki: 18 nM (MTHFD1)[1]; IC50: 96 nM (MTHFD1) and 663 nM (MTHFD2)[3]
LY 345899 could suppress the MTHFD enzyme in the cytoplasm and mitochondria[4].
LY 345899 could disturb the NADPH and redox homeostases and accelerate cell death under oxidative stress, such as hypoxia, or causing in vitro anchorage independence and in vivo impaired tumor growth and metastasis[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SW620 or PDX-based BABL/c nude colorectal cancer (CRC) model[4]
-
Dosage:5-10 mg/kg
-
Administration:Intraperitoneal injection; 5-10 mg/kg; 5 d/wk; 4 weeks
-
Result:Displayed lower cell proliferation indices and higher cell apoptosis.Exhibited no statistically significant weight loss or other signs of acute or delayed toxicity in mice.
Chemical Information
-
CAS No. 10538-99-5
-
Appearance Solid
-
Molecular Weight 471.42
-
Formula C20H21N7O7
-
Color Light yellow to yellow
-
SMILES
O=C(O)[C@@H](NC(C1=CC=C(N2C(N3C4=C(NC(N)=NC4=O)NCC3C2)=O)C=C1)=O)CCC(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma. [Abstract]2025 Mar 14;85(6):1113-1129. PMID: 39804969 -
Nat Commun
Non-canonical dihydrolipoyl transacetylase promotes chemotherapy resistance via mitochondrial tetrahydrofolate signaling. [Abstract]2025 Oct 8;16(1):8932. PMID: 41062483 -
Biomed Pharmacother
Pharmacological targeting of MTHFD2 suppresses NSCLC via the regulation of ILK signaling pathway. [Abstract]2023 May:161:114412. PMID: 36827714 -
Cancers (Basel)
Cysteine and Folate Metabolism Are Targetable Vulnerabilities of Metastatic Colorectal Cancer. [Abstract]2021 Jan 23;13(3):425. PMID: 33498690 -
J Biol Chem
Mitochondrial folate metabolism-mediated α-linolenic acid exhaustion masks liver fibrosis resolution. [Abstract]2023 Jul;299(7):104909. PMID: 37307917 -
bioRxiv
2025 Aug 1:2025.07.29.667470. PMID: 40766369 -
-
Solvent & Solubility
DMSO : 125 mg/mL (265.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Schmidt A, et al. Structures of three inhibitor complexes provide insight into the reaction mechanism of the human methylenetetrahydrofolate dehydrogenase/cyclohydrolase. Biochemistry. 2000 May 30;39(21):6325-35. [Content Brief]
[2]. Tedeschi PM, et al. Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development. Mol Cancer Res. 2015 Oct;13(10):1361-6. [Content Brief]
[3]. Gustafsson R, et al. Crystal Structure of the Emerging Cancer Target MTHFD2 in Complex with a Substrate-Based Inhibitor. Cancer Res. 2017 Feb 15;77(4):937-948. [Content Brief]
[4]. Huai-Qiang Ju, et al.Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst. 2019 Jun 1;111(6):584-596. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1213 mL | 10.6063 mL | 21.2125 mL | 53.0313 mL |
| 5 mM | 0.4243 mL | 2.1213 mL | 4.2425 mL | 10.6063 mL | |
| 10 mM | 0.2121 mL | 1.0606 mL | 2.1213 mL | 5.3031 mL | |
| 15 mM | 0.1414 mL | 0.7071 mL | 1.4142 mL | 3.5354 mL | |
| 20 mM | 0.1061 mL | 0.5303 mL | 1.0606 mL | 2.6516 mL | |
| 25 mM | 0.0849 mL | 0.4243 mL | 0.8485 mL | 2.1213 mL | |
| 30 mM | 0.0707 mL | 0.3535 mL | 0.7071 mL | 1.7677 mL | |
| 40 mM | 0.0530 mL | 0.2652 mL | 0.5303 mL | 1.3258 mL | |
| 50 mM | 0.0424 mL | 0.2121 mL | 0.4243 mL | 1.0606 mL | |
| 60 mM | 0.0354 mL | 0.1768 mL | 0.3535 mL | 0.8839 mL | |
| 80 mM | 0.0265 mL | 0.1326 mL | 0.2652 mL | 0.6629 mL | |
| 100 mM | 0.0212 mL | 0.1061 mL | 0.2121 mL | 0.5303 mL |
Powered by Bioz